Evidence map›Paper›PMID 28032295›Full record

ArticleNeurochemical research2017

Antagonism of Muscarinic Acetylcholine Receptors Alters Synaptic ERK Phosphorylation in the Rat Forebrain.

Li-Min Mao, Henry H Wang, John Q Wang

Open access · greenAbstract read
In one paragraph

Article in Neurochemical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. The cellular model for Alzheimer's disease research: PC12 cells.Frontiers in molecular neuroscience · 2022
    Pooled it
  2. Article
  3. The Aggregation ofBiomedicines · 2024
    Article
  4. Na⁺, K⁺-ATPase Signaling and Bipolar Disorder.International journal of molecular sciences · 2018
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Li-Min MaoDepartment of Basic Medical Science, School of Medicine, University of Missouri-Kansas City, 2411 Holmes Street, Kansas City, MO, 64108, USA.
Henry H WangDepartment of Basic Medical Science, School of Medicine, University of Missouri-Kansas City, 2411 Holmes Street, Kansas City, MO, 64108, USA.
John Q WangDepartment of Basic Medical Science, School of Medicine, University of Missouri-Kansas City, 2411 Holmes Street, Kansas City, MO, 64108, USA. wangjq@umkc.edu.
University of Missouri–Kansas City · US

Funding

REGULATION OF GENE EXPRESSION IN STRIATAL NEURONSR01MH061469 · NIMH · UNIVERSITY OF MISSOURI KANSAS CITY · PI WANG, QIANG · 2001 to 2024
$7.9M
Metabotropic Glutamate Regulation of Amphetamine ActionR01DA010355 · NIDA · UNIVERSITY OF MISSOURI KANSAS CITY · PI WANG, QIANG · 2003 to 2017
$4.6M
METABOTROPIC GLUTAMATE REGULATION OF AMPHETAMINE ACTIONR29DA010355 · NIDA · UNIVERSITY OF MISSOURI KANSAS CITY · PI WANG, QIANG · 1997 to 2001
$198k
NIDA NIH HHS R01 DA010355NIDA NIH HHS R29 DA010355NIMH NIH HHS R01 MH061469
6 · The paper itself

Abstract

Acetylcholine (ACh) is a key transmitter in the mesocorticolimbic circuit. By interacting with muscarinic ACh receptors (mAChR) enriched in the circuit, ACh actively regulates various neuronal and synaptic activities. The extracellular signal-regulated kinase (ERK) is one of members of the mitogen-activated protein kinase family and is subject to the regulation by dopamine receptors, although the regulation of ERKs by limbic mAChRs is poorly understood. In this study, we investigated the role of mAChRs in the regulation of ERK phosphorylation (activation) in the mesocorticolimbic system of adult rat brains in vivo. We targeted a sub-pool of ERKs at synaptic sites. We found that a systemic injection of the mAChR antagonist scopolamine increased phosphorylation of synaptic ERKs in the striatum (caudate putamen and nucleus accumbens) and medial prefrontal cortex (mPFC). Increases in ERK phosphorylation in both forebrain regions were rapid and transient. Notably, pretreatment with a dopamine D1 receptor (D1R) antagonist SCH23390 blocked the scopolamine-stimulated ERK phosphorylation in these brain regions, while a dopamine D2 receptor antagonist eticlopride did not. Scopolamine and SCH23390 did not change the amount of total ERK proteins. These results demonstrate that mAChRs inhibit synaptic ERK phosphorylation in striatal and mPFC neurons under normal conditions. Blockade of this inhibitory mAChR tone leads to the upregulation of ERK phosphorylation likely through a mechanism involving the level of D1R activity.

Indexed as

AnimalsBenzazepinesExtracellular Signal-Regulated MAP KinasesMaleMuscarinic AntagonistsPhosphorylationProsencephalonRatsRats, WistarReceptors, MuscarinicSynapsesSynaptic TransmissionBenzazepinesExtracellular Signal-Regulated MAP KinasesMuscarinic AntagonistsReceptors, MuscarinicSCH 23390AcetylcholineDopamineERKNucleus accumbensPrefrontal cortexSCH23390ScopolamineStriatum

Identifiers

PMID28032295
PMCPMC5405859
OpenAlexW2562504285

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.